Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price target decreased by analysts at Citigroup from $17.00 to $16.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective suggests a potential upside of 73.03% from the company’s previous close.
Other equities analysts have also issued reports about the stock. Oppenheimer restated an “outperform” rating and issued a $15.00 price objective on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Oric Pharmaceuticals in a report on Thursday, April 2nd. Finally, Piper Sandler began coverage on shares of Oric Pharmaceuticals in a report on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oric Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $19.80.
View Our Latest Analysis on ORIC
Oric Pharmaceuticals Stock Down 4.0%
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03). As a group, analysts anticipate that Oric Pharmaceuticals will post -1.34 earnings per share for the current year.
Insider Activity at Oric Pharmaceuticals
In related news, CFO Dominic Piscitelli sold 52,000 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares of the company’s stock, valued at $920,679.48. This trade represents a 43.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.55% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of ORIC. Federation des caisses Desjardins du Quebec grew its position in shares of Oric Pharmaceuticals by 100.0% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares during the last quarter. Assetmark Inc. purchased a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at $37,000. Caitong International Asset Management Co. Ltd grew its position in shares of Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after buying an additional 2,936 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Oric Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after buying an additional 977 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at $60,000. 95.05% of the stock is owned by hedge funds and other institutional investors.
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
Featured Articles
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
